Hsbc Holdings PLC Has $98,000 Stake in Iovance Biotherapeutics, Inc. $IOVA

Hsbc Holdings PLC reduced its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 84.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,484 shares of the biotechnology company’s stock after selling 153,057 shares during the quarter. Hsbc Holdings PLC’s holdings in Iovance Biotherapeutics were worth $98,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Arcataur Capital Management LLC bought a new stake in Iovance Biotherapeutics in the 4th quarter valued at $29,000. Granite Investment Partners LLC acquired a new position in shares of Iovance Biotherapeutics in the fourth quarter valued at $29,000. Motley Fool Asset Management LLC acquired a new position in shares of Iovance Biotherapeutics in the fourth quarter valued at $29,000. M&T Bank Corp bought a new position in shares of Iovance Biotherapeutics in the fourth quarter valued at about $31,000. Finally, SBI Securities Co. Ltd. raised its position in shares of Iovance Biotherapeutics by 169.1% in the fourth quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 7,269 shares during the period. 77.03% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Trading Up 0.9%

Shares of IOVA stock opened at $4.36 on Wednesday. The stock has a market cap of $1.95 billion, a P/E ratio of -4.59 and a beta of 0.71. Iovance Biotherapeutics, Inc. has a 1 year low of $1.76 and a 1 year high of $5.64. The stock has a 50 day simple moving average of $4.32 and a 200 day simple moving average of $3.74.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $71.43 million for the quarter, compared to analyst estimates of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The company’s revenue was up 44.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.36) EPS. Analysts forecast that Iovance Biotherapeutics, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

IOVA has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Chardan Capital lowered their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $8.43.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.